Cytori Reports Sustained Benefit of Cell Therapy in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
203
Cytori Reports Sustained Benefit of Cell Therapy in Erectile Dysfunction Trial

SAN DIEGO, July 09, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq: CYTX ) announced publication in the peer-reviewed journal, Urology , of “A 12-Month Follow-up After a Single Intracavernous Injection of Autologous Adipose-derived Regenerative Cells in Patients with Erectile Dysfunction Following Radical Prostatectomy: An Open-label Phase I Clinical Trial”.

The trial of Adipose-Derived Regenerative Cells (ADRCs) or Cytori Cell Therapy™ in erectile dysfunction (ED) following radical prostatectomy was performed by investigators from the Danish Centre for Regenerative Medicine and Odense University Hospital, Odense, Denmark.

In the trial, 21 patients with ED after radical prostatectomy (RP), with no signs of recovery following conventional therapy, received a single intra-cavernous injection of autologous ADRCs. Six men were incontinent, and 15 were continent at inclusion. Safety and efficacy (sexual function) were evaluated over 12 months through assessment of adverse events and use of validated questionnaires including the International Index of Erectile Function-5 (IIEF-5) and Erection Hardness Score (EHS).

The mean age at baseline was 60.2 years (range 46-69). The approach was deemed safe with no serious adverse events reported. At 12 months following treatment with cell therapy, erectile function assessed using the IIEF-5 showed a statistically significant improvement from a median baseline score of six to a median of eight; p=0.004. Subset analysis of the 15 patients with urinary continence at baseline, showed substantially greater improvement from a median baseline score of six to 13; p=0.012.

At 12 months after surgery, median EHS was unchanged in the combined group of 21 patients. However, patients in the continent subset exhibited statistically significant improvement in EHS from a baseline median score of one to a median of two at 12 months; p=0.03. Further, 53.3% or eight out of 15 continent patients reported recovered function sufficient for completion of intercourse. 

ED and urinary incontinence are serious issues for many men following RP. Cytori Cell Therapy™ is being used to address both of these medical problems. Thus, in addition to the work published in this report, the company has fully enrolled the Autologus Aipose Derived Regenerative Cells for the Treatment of Male Stress Urinary Incontinence (ADRESU) trial of Cytori Cell Therapy™ in men with stress urinary incontinence following RP. The primary endpoint for the ADRESU trial is the percentage of patients who experience greater than 50% reduction in urinary leakage volume from baseline (as measured by the weight of unintended urinary leakage over 24 hours) one year following treatment.  Data from ADRESU are anticipated in the first half of 2019.

ADRESU is an investigator-initiated, multicenter, 45 patient, open-label, single arm clinical trial of Cytori’s ECCI-50 cellular therapeutic, comprised of Celution®-prepared autologous ADRCs and Adipose Cells. The ADRESU trial was based on a promising pilot trial with short-term data of eleven patients published in the  International Journal of Urology  in 2014 and long-term data of 14 patients presented at the International Continence Society in 2017, which “demonstrated that transurethral injection of autologous ADRCs can be a safe and effective treatment modality for postprostatectomy incontinence”.  Details of the ADRESU protocol and trial can be found on  BMC Urology , clinicaltrials.gov  and the  University Hospital Medical Information Network website .

About Cytori Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications using technology that allows Cytori to use the benefits of its encapsulation platform to develop novel therapeutic strategies and reformulate other drugs to optimize their clinical properties. For more information, visit www.cytori.com .

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. These statements are subject to risks and uncertainties that could cause Cytori’s actual results and financial position to differ materially. Such statements, including, without limitation, statements regarding Cytori Cell Therapy’s potential to provide benefits across multiple disease states, the conduct of the ADRESU trial and timing of anticipated trial data, are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. These risks and uncertainties, which include inherent uncertainties in conduct of clinical studies and trials and the results of such trials (including risks that further studies may not support efficacy or safety of Cytori Cell Therapy), risks associated with clinical use of Cytori Cell Therapy in studies and trials not controlled by Cytori, risks to Cytori’s intellectual property portfolio are described under the heading "Risk Factors" in Cytori's Securities and Exchange Commission Filings on Form 10-K and Form 10-Q. Cytori assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

CONTACT CYTORI THERAPEUTICS Tiago Girao +1.858.458.0900 ir@cytori.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 208

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 308

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 241

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 245

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 485

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 374

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 284

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 334

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 272

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 374

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading

Top 5 Most Recently Viewed Articles

Robinhood's Rise: A Shift from Meme Stock to Financial Powerhouse

Updated Category News Views 246

Robinhood's Transformation in the Financial Landscape Recently, Robinhood Markets announced a significant upgrade to its stock, with Barclays analyst Benjamin Budish raising the rating from Underweight to Equal-Weight. This adjustment also includes an increase in the price target from $18 to $20, indicating a positive outlook for the company. A Seasoned Player in the...

Continue Reading
Transforming Global Education: Italy and Nigeria's Bold Initiative

Updated Category News Views 271

Italy and Nigeria Launch a $5 Billion Education Campaign In a collaborative effort, Italy and Nigeria, in partnership with the Global Partnership for Education (GPE), have launched a bold campaign aimed at transforming education for 750 million children worldwide. This ambitious initiative was announced at a high-profile event during the United Nations General Assembly,...

Continue Reading
KBR Secures Critical Engineering Contract for LNG Project

Updated Category News Views 248

KBR's New Engineering Milestone in LNG Development HOUSTON — KBR announced today that it has secured a major contract from INPEX Masela Ltd. for front-end engineering design (FEED) work on the Abadi LNG project in Indonesia. Understanding the Abadi LNG Project The Abadi LNG project is poised to make significant contributions to Indonesia’s energy sector, with a peak...

Continue Reading
Investors Urged to Act Following Class Action Against CAPR

Updated Category News Views 209

Investors Encouraged to Take Action Against Capricor Therapeutics Bragar Eagel & Squire, P.C. is reaching out to investors who may have suffered losses due to recent developments with Capricor Therapeutics (CAPR). Individuals who purchased or acquired securities during the specified class period are urged to connect with the firm's litigation partner, Brandon Walker, to...

Continue Reading
Celebrating Dr. Kristina K. Roberts as a Pinnacle Lifetime Member

Updated Category News Views 218

Dr. Kristina K. Roberts Recognized for Excellence in Mental Health In a significant acknowledgment of her contributions to the field of mental health care, Dr. Kristina K. Roberts, Psy.D. has been honored as a Pinnacle Lifetime Member by The Inner Circle. This prestigious recognition illustrates her unwavering commitment and profound impact on the lives of her patients....

Continue Reading